Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy

The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells f...

Full description

Saved in:
Bibliographic Details
Published inAdvanced science Vol. 11; no. 23; pp. e2310309 - n/a
Main Authors Li, Youyou, Liu, Jing, Chen, Yimei, Weichselbaum, Ralph R., Lin, Wenbin
Format Journal Article
LanguageEnglish
Published Germany John Wiley & Sons, Inc 01.06.2024
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti‐Warburg effect of Er sensitizes tumor cells to Cu‐mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death‐ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple‐negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies. This paper reports a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis. CuP/Er induces strong immunogenic cell death, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple‐negative breast cancer and prevent tumor metastasis.
AbstractList The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti‐Warburg effect of Er sensitizes tumor cells to Cu‐mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death‐ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple‐negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies. This paper reports a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis. CuP/Er induces strong immunogenic cell death, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple‐negative breast cancer and prevent tumor metastasis.
The recent discovery of copper-mediated and mitochondrion-dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core-shell nanoparticle, CuP/Er, for the co-delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti-Warburg effect of Er sensitizes tumor cells to Cu-mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death-ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple-negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies.The recent discovery of copper-mediated and mitochondrion-dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core-shell nanoparticle, CuP/Er, for the co-delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti-Warburg effect of Er sensitizes tumor cells to Cu-mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death-ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple-negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies.
The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti‐Warburg effect of Er sensitizes tumor cells to Cu‐mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death‐ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple‐negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies.
Abstract The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death for cancer therapy. Here the design of a core‐shell nanoparticle, CuP/Er, for the co‐delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported. The anti‐Warburg effect of Er sensitizes tumor cells to Cu‐mediated cuproptosis, leading to irreparable mitochondrial damage by depleting glutathione and enhancing lipid peroxidation. CuP/Er induces strong immunogenic cell death, enhances antigen presentation, and upregulates programmed death‐ligand 1 expression. Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple‐negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies.
Author Weichselbaum, Ralph R.
Chen, Yimei
Lin, Wenbin
Liu, Jing
Li, Youyou
AuthorAffiliation 1 Department of Chemistry The University of Chicago Chicago IL 60637 USA
2 Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research The University of Chicago Chicago IL 60637 USA
AuthorAffiliation_xml – name: 2 Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research The University of Chicago Chicago IL 60637 USA
– name: 1 Department of Chemistry The University of Chicago Chicago IL 60637 USA
Author_xml – sequence: 1
  givenname: Youyou
  surname: Li
  fullname: Li, Youyou
  organization: The University of Chicago
– sequence: 2
  givenname: Jing
  surname: Liu
  fullname: Liu, Jing
  organization: The University of Chicago
– sequence: 3
  givenname: Yimei
  surname: Chen
  fullname: Chen, Yimei
  organization: The University of Chicago
– sequence: 4
  givenname: Ralph R.
  surname: Weichselbaum
  fullname: Weichselbaum, Ralph R.
  organization: The University of Chicago
– sequence: 5
  givenname: Wenbin
  orcidid: 0000-0001-7035-7759
  surname: Lin
  fullname: Lin, Wenbin
  email: wenbinlin@uchicago.edu
  organization: The University of Chicago
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38477411$$D View this record in MEDLINE/PubMed
BookMark eNqFks1vFCEYh4mpsR_26tFM4sXLrnwOcDLNanWTRk2qvRIG3tnOZhZGmKnZ_vVSd920XjwBLw9P-MF7io5CDIDQK4LnBGP6zvq7PKeYMoIZ1s_QCSVazZji_OjR_Bid57zGGBPBJCfqBTouZVmm5ATdfLEhDjaNneshV9fbAGnV3UN1CSnFYYy5y5UNvlpMw2E9xupbHCGMnR2hWtjgIFXLzWYKcbyFZIftS_S8tX2G8_14hn5cfvy--Dy7-vppubi4mjmuhJo1LaV1o5Qg0lMteKubFkusFNaEOyuc0L6WrQCnnG6d9FwQYL6x2NaYK8fO0HLn9dGuzZC6jU1bE21n_hRiWpl9NtPImminRKtIwy0FK4DZ2ragGRbe-eJ6v3MNU7MB70q-ZPsn0qc7obs1q3hnCCFKKs2L4e3ekOLPCfJoNl120Pc2QJyyKRHrWlFZq4K--QddxymF8laG4VoLqoiWhZrvKJdizgnaw20INg8tYB5awBxaoBx4_TjDAf_74QXgO-BX18P2Pzpz8eHmWkqh2G_2TsAp
Cites_doi 10.1038/s41568-021-00339-z
10.1038/nrd.2017.22
10.1016/j.immuni.2022.04.016
10.1021/acsnano.3c00891
10.1038/s41573-022-00520-5
10.1146/annurev-immunol-032712-100008
10.1002/adfm.202214998
10.1038/nri3754
10.1016/j.addr.2022.114115
10.1111/imr.13276
10.1186/s12951-022-01719-9
10.1038/s41586-022-05661-6
10.1016/j.cell.2013.12.010
10.1158/1078-0432.CCR-19-2230
10.1002/adma.202212267
10.1126/science.abf0529
10.7554/eLife.02523
10.1016/j.cell.2015.07.017
10.1158/jcr.1925.148
10.1038/nnano.2017.113
10.1038/s41565-019-0485-z
10.1016/j.chembiol.2019.01.008
10.1038/nature05859
10.1016/j.tibs.2015.12.001
10.1038/nature13611
10.1016/S1535-6108(03)00050-3
10.1039/c0cs00227e
10.1186/s13045-022-01392-3
10.1016/j.ccell.2015.05.007
10.1021/ja106855m
10.1038/s41565-018-0271-3
10.1186/s12951-021-01073-2
10.1021/acs.chemrev.5b00125
10.1016/j.cell.2012.03.042
10.1038/ncomms5182
10.3390/cancers12123594
10.1038/nature24057
10.1038/s41598-022-22962-y
10.1016/0022-1759(83)90308-3
10.1074/jbc.M112.433847
10.1002/advs.201802012
10.1002/advs.202201614
10.1016/j.molcel.2014.09.025
10.1016/j.cell.2015.07.016
10.1124/mol.109.063172
10.1186/s13046-023-02720-2
10.1021/jacs.6b09538
10.1016/j.addr.2022.114357
10.1038/s41571-020-0341-y
10.1002/0471142735.im2002s39
10.1021/jacs.9b03457
10.1038/s41565-022-01225-x
10.1186/s12943-018-0928-4
10.1038/s41587-020-0707-9
10.1038/nnano.2016.164
10.3390/ijms21031069
ContentType Journal Article
Copyright 2024 The Authors. Advanced Science published by Wiley‐VCH GmbH
2024 The Authors. Advanced Science published by Wiley‐VCH GmbH.
2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Authors. Advanced Science published by Wiley‐VCH GmbH
– notice: 2024 The Authors. Advanced Science published by Wiley‐VCH GmbH.
– notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7XB
88I
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
HCIFZ
M2O
M2P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1002/advs.202310309
DatabaseName Wiley Online Library Open Access
Wiley Online Library website
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
Research Library
Science Database
Research Library (Corporate)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Science Journals (Alumni Edition)
ProQuest Central Student
ProQuest Central Basic
ProQuest Central Essentials
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
MEDLINE
Publicly Available Content Database


Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
EISSN 2198-3844
EndPage n/a
ExternalDocumentID oai_doaj_org_article_b7619c85f81b4a2ea5e3a6afe9305dcd
10_1002_advs_202310309
38477411
ADVS7758
Genre article
Journal Article
GrantInformation_xml – fundername: National Cancer Institute
  funderid: 1R01CA279802; 1R01CA276307
– fundername: NCI NIH HHS
  grantid: R01 CA276307
– fundername: NCI NIH HHS
  grantid: R01 CA279802
– fundername: NCI NIH HHS
  grantid: 1R01CA276307
– fundername: NCI NIH HHS
  grantid: 1R01CA279802
GroupedDBID 0R~
1OC
24P
53G
5VS
88I
8G5
AAFWJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACGFS
ACXQS
ADBBV
ADKYN
ADZMN
ADZOD
AEEZP
AEQDE
AFBPY
AFKRA
AFPKN
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
AZQEC
BCNDV
BENPR
BPHCQ
BRXPI
CCPQU
DWQXO
EBS
GNUQQ
GODZA
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
KQ8
M2O
M2P
O9-
OK1
PIMPY
PQQKQ
PROAC
ROL
RPM
WIN
CGR
CUY
CVF
ECM
EIF
EJD
ITC
NPM
AAYXX
CITATION
3V.
7XB
8FK
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c4858-bf226b88517d2954f9bf070880914ca5c59d67f5ec8c9fc7d451e3dba0a6048c3
IEDL.DBID RPM
ISSN 2198-3844
IngestDate Tue Oct 22 15:02:22 EDT 2024
Tue Sep 17 21:28:56 EDT 2024
Sat Oct 26 04:52:41 EDT 2024
Thu Oct 10 18:09:00 EDT 2024
Fri Dec 06 09:48:32 EST 2024
Sat Nov 02 12:30:53 EDT 2024
Sat Aug 24 00:57:38 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 23
Keywords ferroptosis
nanoparticles
cuproptosis
immunotherapy
Language English
License Attribution
2024 The Authors. Advanced Science published by Wiley‐VCH GmbH.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4858-bf226b88517d2954f9bf070880914ca5c59d67f5ec8c9fc7d451e3dba0a6048c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-7035-7759
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11187894/
PMID 38477411
PQID 3069528197
PQPubID 4365299
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_b7619c85f81b4a2ea5e3a6afe9305dcd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11187894
proquest_miscellaneous_2956682768
proquest_journals_3069528197
crossref_primary_10_1002_advs_202310309
pubmed_primary_38477411
wiley_primary_10_1002_advs_202310309_ADVS7758
PublicationCentury 2000
PublicationDate 2024-06-01
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: 2024-06-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Weinheim
– name: Hoboken
PublicationTitle Advanced science
PublicationTitleAlternate Adv Sci (Weinh)
PublicationYear 2024
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2022; 375
2023; 35
2021; 21
2023; 33
2019; 14
2020; 17
2013; 288
2019; 18
2020; 12
2022; 20
2022; 21
2017; 551
2014; 5
2014; 3
2021; 39
2019; 26
2003; 3
1983; 65
2016; 41
2014; 14
2023; 614
2014; 56
2015; 162
2014; 514
2010; 77
2019; 6
2007; 447
2023; 17
2011; 40
2024; 321
2019; 141
2012; 149
2014; 156
2016; 11
2023; 42
2022; 187
2015; 28
1925; 9
2022; 182
2000; 39
2015; 115
2017; 16
2013; 31
2022; 9
2017; 12
2021; 19
2010; 132
2022; 12
2020; 26
2022; 15
2016; 138
2022; 55
2020; 21
2022; 17
2018; 13
e_1_2_7_5_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_17_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_1_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
e_1_2_7_50_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_52_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_54_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_56_1
e_1_2_7_37_1
e_1_2_7_39_1
e_1_2_7_6_1
e_1_2_7_4_1
e_1_2_7_8_1
e_1_2_7_18_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_10_1
e_1_2_7_46_1
e_1_2_7_48_1
e_1_2_7_27_1
e_1_2_7_29_1
e_1_2_7_51_1
e_1_2_7_30_1
e_1_2_7_53_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_55_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_38_1
References_xml – volume: 614
  start-page: 349
  year: 2023
  publication-title: Nature.
– volume: 13
  start-page: 1174
  year: 2018
  publication-title: Nat. Nanotechnol.
– volume: 3
  year: 2014
  publication-title: eLife.
– volume: 11
  start-page: 977
  year: 2016
  publication-title: Nat. Nanotechnol.
– volume: 77
  start-page: 887
  year: 2010
  publication-title: Mol. Pharmacol.
– volume: 447
  start-page: 865
  year: 2007
  publication-title: Nature.
– volume: 39
  year: 2000
  publication-title: Curr. Protoc. Immunol.
– volume: 514
  start-page: 628
  year: 2014
  publication-title: Nature.
– volume: 141
  start-page: 9937
  year: 2019
  publication-title: J. Am. Chem. Soc.
– volume: 17
  start-page: 395
  year: 2020
  publication-title: Nat. Rev. Clin. Oncol.
– volume: 132
  year: 2010
  publication-title: J. Am. Chem. Soc.
– volume: 20
  start-page: 513
  year: 2022
  publication-title: J. Nanobiotechnol.
– volume: 5
  start-page: 4182
  year: 2014
  publication-title: Nat. Commun.
– volume: 12
  start-page: 3594
  year: 2020
  publication-title: Cancers.
– volume: 16
  start-page: 487
  year: 2017
  publication-title: Nat. Rev. Drug Discovery.
– volume: 288
  year: 2013
  publication-title: J. Biol. Chem.
– volume: 33
  year: 2023
  publication-title: Adv. Funct. Mater.
– volume: 28
  start-page: 42
  year: 2015
  publication-title: Cancer Cell.
– volume: 162
  start-page: 552
  year: 2015
  publication-title: Cell.
– volume: 182
  year: 2022
  publication-title: Adv. Drug Delivery Rev.
– volume: 551
  start-page: 115
  year: 2017
  publication-title: Nature.
– volume: 12
  year: 2022
  publication-title: Sci. Rep.
– volume: 115
  year: 2015
  publication-title: Chem. Rev.
– volume: 6
  year: 2019
  publication-title: Adv. Sci.
– volume: 17
  start-page: 7979
  year: 2023
  publication-title: ACS Nano.
– volume: 14
  start-page: 799
  year: 2019
  publication-title: Nat. Nanotechnol.
– volume: 3
  start-page: 285
  year: 2003
  publication-title: Cancer Cell.
– volume: 55
  start-page: 982
  year: 2022
  publication-title: Immunity.
– volume: 15
  start-page: 174
  year: 2022
  publication-title: J. Hematol. Oncol.
– volume: 26
  start-page: P623
  year: 2019
  publication-title: Cell Chem. Biol.
– volume: 17
  start-page: 1322
  year: 2022
  publication-title: Nat. Nanotechnol.
– volume: 14
  start-page: 719
  year: 2014
  publication-title: Nat. Rev. Immunol.
– volume: 39
  start-page: 357
  year: 2021
  publication-title: Nat. Biotechnol.
– volume: 162
  start-page: 540
  year: 2015
  publication-title: Cell.
– volume: 56
  start-page: 414
  year: 2014
  publication-title: Mol. Cell.
– volume: 12
  start-page: 877
  year: 2017
  publication-title: Nat. Nanotechnol.
– volume: 375
  start-page: 1254
  year: 2022
  publication-title: Science.
– volume: 149
  start-page: 1060
  year: 2012
  publication-title: Cell.
– volume: 321
  start-page: 211
  year: 2024
  publication-title: Immunol. Rev.
– volume: 26
  start-page: 2065
  year: 2020
  publication-title: Clin. Cancer Res.
– volume: 35
  year: 2023
  publication-title: Adv. Mater.
– volume: 9
  year: 2022
  publication-title: Adv. Sci.
– volume: 187
  year: 2022
  publication-title: Adv. Drug Delivery Rev.
– volume: 21
  start-page: 1069
  year: 2020
  publication-title: Int. J. Mol. Sci.
– volume: 65
  start-page: 109
  year: 1983
  publication-title: J. Immunol. Methods.
– volume: 31
  start-page: 51
  year: 2013
  publication-title: Annu. Rev. Immunol.
– volume: 18
  start-page: 10
  year: 2019
  publication-title: Mol. Cancer.
– volume: 21
  start-page: 799
  year: 2022
  publication-title: Nat. Rev. Drug Discovery.
– volume: 9
  start-page: 148
  year: 1925
  publication-title: J. Cancer Res.
– volume: 40
  start-page: 3638
  year: 2011
  publication-title: Chem. Soc. Rev.
– volume: 42
  start-page: 142
  year: 2023
  publication-title: J. Exp. Clin. Cancer Res.
– volume: 138
  year: 2016
  publication-title: J. Am. Chem. Soc.
– volume: 41
  start-page: 211
  year: 2016
  publication-title: Trends Biochem. Sci.
– volume: 21
  start-page: 298
  year: 2021
  publication-title: Nat. Rev. Cancer.
– volume: 19
  start-page: 328
  year: 2021
  publication-title: J. Nanobiotechnol.
– volume: 156
  start-page: 317
  year: 2014
  publication-title: Cell.
– ident: e_1_2_7_40_1
  doi: 10.1038/s41568-021-00339-z
– ident: e_1_2_7_53_1
  doi: 10.1038/nrd.2017.22
– ident: e_1_2_7_39_1
  doi: 10.1016/j.immuni.2022.04.016
– ident: e_1_2_7_19_1
  doi: 10.1021/acsnano.3c00891
– ident: e_1_2_7_44_1
  doi: 10.1038/s41573-022-00520-5
– ident: e_1_2_7_38_1
  doi: 10.1146/annurev-immunol-032712-100008
– ident: e_1_2_7_30_1
  doi: 10.1002/adfm.202214998
– ident: e_1_2_7_41_1
  doi: 10.1038/nri3754
– ident: e_1_2_7_23_1
  doi: 10.1016/j.addr.2022.114115
– ident: e_1_2_7_32_1
  doi: 10.1111/imr.13276
– ident: e_1_2_7_56_1
  doi: 10.1186/s12951-022-01719-9
– ident: e_1_2_7_4_1
  doi: 10.1038/s41586-022-05661-6
– ident: e_1_2_7_17_1
  doi: 10.1016/j.cell.2013.12.010
– ident: e_1_2_7_43_1
  doi: 10.1158/1078-0432.CCR-19-2230
– ident: e_1_2_7_33_1
  doi: 10.1002/adma.202212267
– ident: e_1_2_7_3_1
  doi: 10.1126/science.abf0529
– ident: e_1_2_7_15_1
  doi: 10.7554/eLife.02523
– ident: e_1_2_7_10_1
  doi: 10.1016/j.cell.2015.07.017
– ident: e_1_2_7_6_1
  doi: 10.1158/jcr.1925.148
– ident: e_1_2_7_21_1
  doi: 10.1038/nnano.2017.113
– ident: e_1_2_7_27_1
  doi: 10.1038/s41565-019-0485-z
– ident: e_1_2_7_18_1
  doi: 10.1016/j.chembiol.2019.01.008
– ident: e_1_2_7_16_1
  doi: 10.1038/nature05859
– ident: e_1_2_7_5_1
  doi: 10.1016/j.tibs.2015.12.001
– ident: e_1_2_7_12_1
  doi: 10.1038/nature13611
– ident: e_1_2_7_13_1
  doi: 10.1016/S1535-6108(03)00050-3
– ident: e_1_2_7_26_1
  doi: 10.1039/c0cs00227e
– ident: e_1_2_7_1_1
  doi: 10.1186/s13045-022-01392-3
– ident: e_1_2_7_11_1
  doi: 10.1016/j.ccell.2015.05.007
– ident: e_1_2_7_24_1
  doi: 10.1021/ja106855m
– ident: e_1_2_7_20_1
  doi: 10.1038/s41565-018-0271-3
– ident: e_1_2_7_55_1
  doi: 10.1186/s12951-021-01073-2
– ident: e_1_2_7_28_1
  doi: 10.1021/acs.chemrev.5b00125
– ident: e_1_2_7_14_1
  doi: 10.1016/j.cell.2012.03.042
– ident: e_1_2_7_29_1
  doi: 10.1038/ncomms5182
– ident: e_1_2_7_47_1
  doi: 10.3390/cancers12123594
– ident: e_1_2_7_7_1
  doi: 10.1038/nature24057
– ident: e_1_2_7_34_1
  doi: 10.1038/s41598-022-22962-y
– ident: e_1_2_7_45_1
  doi: 10.1016/0022-1759(83)90308-3
– ident: e_1_2_7_37_1
  doi: 10.1074/jbc.M112.433847
– ident: e_1_2_7_54_1
  doi: 10.1002/advs.201802012
– ident: e_1_2_7_52_1
  doi: 10.1002/advs.202201614
– ident: e_1_2_7_8_1
  doi: 10.1016/j.molcel.2014.09.025
– ident: e_1_2_7_9_1
  doi: 10.1016/j.cell.2015.07.016
– ident: e_1_2_7_48_1
  doi: 10.1124/mol.109.063172
– ident: e_1_2_7_35_1
  doi: 10.1186/s13046-023-02720-2
– ident: e_1_2_7_51_1
  doi: 10.1021/jacs.6b09538
– ident: e_1_2_7_22_1
  doi: 10.1016/j.addr.2022.114357
– ident: e_1_2_7_2_1
  doi: 10.1038/s41571-020-0341-y
– ident: e_1_2_7_46_1
  doi: 10.1002/0471142735.im2002s39
– ident: e_1_2_7_36_1
  doi: 10.1021/jacs.9b03457
– ident: e_1_2_7_31_1
  doi: 10.1038/s41565-022-01225-x
– ident: e_1_2_7_42_1
  doi: 10.1186/s12943-018-0928-4
– ident: e_1_2_7_49_1
  doi: 10.1038/s41587-020-0707-9
– ident: e_1_2_7_25_1
  doi: 10.1038/nnano.2016.164
– ident: e_1_2_7_50_1
  doi: 10.3390/ijms21031069
SSID ssj0001537418
Score 2.4101133
Snippet The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death...
The recent discovery of copper-mediated and mitochondrion-dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell death...
Abstract The recent discovery of copper‐mediated and mitochondrion‐dependent cuproptosis has aroused strong interest in harnessing this novel mechanism of cell...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage e2310309
SubjectTerms Animals
Cancer therapies
Cell death
Cell Line, Tumor
Copper
cuproptosis
Disease Models, Animal
Female
Ferroptosis
Ferroptosis - drug effects
Humans
Immunotherapy
Immunotherapy - methods
Lipid peroxidation
Lipids
Metabolism
Mice
Microemulsions
Nanoparticles
Piperazines
Proteins
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - immunology
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB1KTr2Upm1aN2lRIJD0YGJbkiUd26VLmkMpJCm5CX3SvdjLrreQ_vqObK_ZpYVccrRlmWFGo3mDRm8AznjpMagXMXeSupzRIHJraJnXNCqR4ilOS9UW3-urO3Z9z-93Wn2lmrCBHnhQ3KVNebaTPCK-YqYKhgdqahODwpXqne9336LaSaaG-8E00bJsWRqL6tL434mdu-r7aqm9KNST9f8PYf5bKLkLYPsINH8JL0boSD4PIh_Cs9C8gsPROdfkYmSQ_vQafuKeicnwWPNGbh7SBb_Fn0DmYbVql127XqyJaTyZbZbTc9eSH22XiocQfpJZWg0r8i1dHxkvaT28gbv519vZVT42UMgdk1zmNqIdrERQJXw6z4vKRnRxdFlVMme448rXIvLgpFPRCc94Gai3pjA1erajR3DQtE14B8QwwXB-ZMxEZmlp0b6mEsEWtPKIajI43ypULweeDD0wIlc6qV5Pqs_gS9L39FXit-5foNX1qBn9mNUzONlaS49Ot9aY_SieDgZFBqfTMLpLOgMxTWg3KAbmg7WsMMnK4O1g3EkSipEaV02Zgdwz-56o-yPN4ldPyV2mru1SsQzyfoU8ogONmONGYKr2_imUcQzP8c9sKGA7gYNutQkfECp19mPvFX8BuOgS2Q
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7B9sIFUZ6BgoyEBBysbmI7cU4VXXVVOFQVpai3yE_YS7IkWaTy6ztOvCkrEBwTx5IzD89ne_wNwBuRWgzqc0-NZIZy5gqqFUtpznxZhHiK3UK2xVl-esk_XYmruOHWxbTK7Zw4TNS2MWGP_BChbSnCqU9xtP5BQ9WocLoaS2jchb0sZVLOYO_45Oz88-0ui2CBnmXL1jjPDpX9GVi6s6G-VrkTjQbS_r8hzT8TJn8HskMkWj6A-xFCkg-jzvfhjqsfwn500o68i0zS7x_BV5w7cVEcc9_IxXW46Lf65cjStW2z7ptu1RFVW7LYrKfnviHnTR-SiBCGkkWwipZ8DNdI4mWt68dwuTz5sjilsZACNVwKSbVHfWiJ4Kqw4VzPl9qjq6Prlik3ShhR2rzwwhlpSm8Ky0XqmNVqrnL0cMOewKxuavcMiOIFx_6ec-W5ZqlGPauscHrOMovoJoG3W4FW65EvoxqZkbMqiL6aRJ_AcZD39FXguR5eNO23Kkqm0mGXxUjhEV1zlTklHFO58q7Eecoam8DBVltVdL6uujWVBF5Pzeg24SxE1a7Z4DBwXZjLDBdbCTwdlTuNhGHERqtJE5A7at8Z6m5Lvfo-UHOnoXq7LHkCdLCQ_8igQuxxUeCS7fm__-MF3MM-fExRO4BZ327cSwRDvX4VLf4GUpsKnQ
  priority: 102
  providerName: ProQuest
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BuXBBlGdoQUZCAg5RN7GdOMd2xapwQJVKUW-Rn7CXZJVkK7W_vjNJNm0EEuKYp6wZf_Y39vgbgA8ycTipL0JsFbex4D6PjeZJnPFQ5DSf4meUbfE9O70Q3y7l5b1T_IM-xLTgRsjox2sCuDbt0Z1oqHZXJLed9oWyiofwCLlNRjUMUnF2t8oiOcmzUIU5jK5jroTYKTcu0qP5L2YzUy_g_zfW-Wfy5H1S289Kq6fwZKST7Hjw_z488NUz2B8B27JPo6r05-fwE8dRDJDHPDh2fk2H_tY3nq1809Sbrm7XLdOVY8vtZrruanZWd5RQhJSULamHNOwrHSkZD25dv4CL1Zcfy9N4LKoQW6Gkik1A3xiFRCt3tMcXChMQ9gjjIhFWSysLl-VBeqtsEWzuhEw8d0YvdIZot_wl7FV15V8D0yIX-H0QQgdheGLQ5zrNvVnw1CHTieDjzqDlZtDOKAeV5LQk05eT6SM4IXtPb5HmdX-jbn6Vo2VKQysuVsmATFvo1Gvpuc508AWOWc66CA533ipHILYlRkSFpM3CPIL302OEEO2L6MrXW2wGxoiZSjHwiuDV4NypJdhjkCAnSQRq5vZZU-dPqvXvXqY7oUruqhARxH0P-YcNSuQh5zmGb2_-8_0DeIw3xZC_dgh7XbP1b5EpdeZdD4ZbHmwNpg
  priority: 102
  providerName: Wiley-Blackwell
Title Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadvs.202310309
https://www.ncbi.nlm.nih.gov/pubmed/38477411
https://www.proquest.com/docview/3069528197
https://www.proquest.com/docview/2956682768
https://pubmed.ncbi.nlm.nih.gov/PMC11187894
https://doaj.org/article/b7619c85f81b4a2ea5e3a6afe9305dcd
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6y6aWX0vTpJllUKLQ9OLu2JD-OyZIlLTQsTVNyM3qmC429eL2B9Nd3JD_I0kAhR79lzYzmG2nmE8AHHml06lMbqoyqkFGThlLQKEyozVPnT_Exl21xnpxdsq9X_GoHkr4WxiftK7k8Kn_fHJXLXz63cnWjJn2e2GTxbRa5PbKznE1GMEL_ey9Gb2uDqaNk6Rkap_FE6FvHzB37PbUcTyjFMRnvibackefsfwho_psveR_Hekc0fw7POgRJjtuW7sGOKV_AXmeja_KpI5L-_BJ-4tCJMXH3S-TiztX5Lf8YMjd1Xa2aar1cE1FqMtushuOmIouqcTlEiELJzClFTb64KpKuVuvuFVzOT3_MzsJuH4VQsYxnobQoDpkhtkq1W9azubRo6Wi5ecSU4IrnOkktNypTuVWpZjwyVEsxFQkauKKvYbesSvMWiGApw-ctY8IySSOJYhZxauSUxhrBTQAf-w4tVi1dRtESI8eFk0IxSCGAE9ffw12O5tqfqOrrouuZQrpJFpVxi-CaidgIbqhIhDU5DlNa6QAOemkVne2tCwyCcu7WB9MA3g-X0WrcUogoTbXBZmBYmGQxxloBvGmFO7SkV44Asi2xbzV1-woqqmfm7hUzgNBryH_6oEDocZFixPbu8Z_ah6f4PtZmrx3AblNvzCHipEaOYRSzxRienJyeL76P_WzD2JvKXyChFfY
link.rule.ids 230,314,727,780,784,864,885,2102,11562,21388,27924,27925,33744,33745,43805,46052,46476,50814,50923,53791,53793,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7B9gAXRHmmFDASEnCIuontPE6IrrraQllVtEW9WX7CXpLtJotUfj3jxJuyAsExcSw58_B8tsffALzmicGgPnaxLqiOGbV5rCRN4oy6MvfxFLv5bIt5NrtgHy_5Zdhwa0Ja5WZO7CZqU2u_R36A0Lbk_tQnf7-8in3VKH-6Gkpo3IYdz5zOR7BzeDQ__XKzy8Kpp2fZsDWO0wNpfniW7rSrr1VuRaOOtP9vSPPPhMnfgWwXiab34V6AkORDr_NduGWrB7AbnLQhbwOT9LuH8BXnTlwUh9w3cnbtL_otfloytatVvWzrZtEQWRkyWS-H57Ymp3Xrk4gQhpKJt4oVOfbXSMJlretHcDE9Op_M4lBIIdas4EWsHOpDFQiucuPP9VypHLo6um6ZMC255qXJcsetLnTpdG4YTyw1So5lhh6u6WMYVXVlnwKRLGfY3zEmHVM0UahnmeZWjWlqEN1E8GYjULHs-TJEz4ycCi96MYg-gkMv7-Erz3PdvahX30SQjFB-l0UX3CG6ZjK1klsqM-lsifOU0SaC_Y22RHC-RtyYSgSvhmZ0G38WIitbr3EYuC7MihQXWxE86ZU7jIRixEarSSIottS-NdTtlmrxvaPmTnz19qJkEcSdhfxHBgKxx1mOS7a9f__HS7gzO_98Ik6O55-ewV3sz_p0tX0Ytau1fY7AqFUvgvX_AutPDYU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB7BVkJcEOWZUsBISMAh2iS28zghunTVAlqtKEW9RX7CXpJtkkUqv55x4k1ZgeCYOJaceXg-2-NvAF7yWGNQj2yocqpCRk0WSkHjMKW2yFw8xW4u22KRnpyzDxf8wuc_tT6tcjsn9hO1rpXbI58itC24O_XJptanRSzfz9-uL0NXQcqdtPpyGjdhD6NilExg7-h4sfx8vePCqaNq2TI3RslU6B-OsTvpa20VO5GpJ_D_G-r8M3nyd1DbR6X5Xbjj4SR5N-h_H26Y6h7se4dtyWvPKv3mPnzFeRQXyD4PjpxduUt_q5-GzE3T1OuublctEZUms816fO5qsqw7l1CEkJTMnIU05NRdKfEXt64ewPn8-MvsJPRFFULFcp6H0qJuZI5AK9PujM8W0qLboxsXMVOCK17oNLPcqFwVVmWa8dhQLUUkUvR2RR_CpKor8xiIYBnD_pYxYZmksUSdiyQzMqKJRqQTwKutQMv1wJ1RDizJSelEX46iD-DIyXv8ynFe9y_q5lvpJVNKt-Oicm4RaTORGMENFamwpsA5SysdwOFWW6V3xLa8NpsAXozN6ELuXERUpt7gMHCNmOYJLrwCeDQodxwJxeiNVhMHkO-ofWeouy3V6ntP0x27Su55wQIIewv5jwxKxCFnGS7fDv79H8_hFhp--el08fEJ3MbubMhcO4RJ12zMU8RInXzmjf8XbDARsg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nanoparticles+Synergize+Ferroptosis+and+Cuproptosis+to+Potentiate+Cancer+Immunotherapy&rft.jtitle=Advanced+science&rft.au=Li%2C+Youyou&rft.au=Liu%2C+Jing&rft.au=Chen%2C+Yimei&rft.au=Weichselbaum%2C+Ralph+R.&rft.date=2024-06-01&rft.issn=2198-3844&rft.eissn=2198-3844&rft.volume=11&rft.issue=23&rft_id=info:doi/10.1002%2Fadvs.202310309&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_advs_202310309
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2198-3844&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2198-3844&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2198-3844&client=summon